Oura Files S-1 for Nasdaq Listing, Reporting $1.21 Billion in Revenue for the Nine Months Ended June 30, 2026
The Finland-founded smart-ring maker plans to trade as OURA and disclosed 5.0 million paid members, a $985.0 million deemed dividend to preferred holders, and the U.S. Department of Defense as its largest enterprise customer.
A Ring That Wants to Be Judged Like Software
Oura filed its paperwork with the SEC on September 3, 2026, asking to sell shares on the Nasdaq under the ticker OURA[1][2]. The filing lands two very different numbers in the same document. One says the company made $60.8 million over nine months. The other says it lost $924.3 million[2]. Both are true, and the gap between them is the first thing worth understanding about this IPO.
The loss isn't from burning cash. It comes from a $985.0 million "deemed dividend," an accounting charge tied to how Oura restructured its preferred shares before going public[2]. PitchBook reports the company bought back more than $1 billion from early investors ahead of the filing, letting those insiders cash out at a private price before public shareholders get a shot[17]. The $985 million is the paper trail that transaction left behind. Read past the headline loss, and the underlying business is growing fast and turning a real profit.
The Case for a $16 Billion Ring
Oura sold 3.1 million rings over the nine months ending June 30, 2026, and collected $1.21 billion doing it — up 74% from $697.6 million a year earlier[2][3]. Fiscal 2025 revenue was $907.9 million, more than double the $406.8 million from the year before[2]. Paid membership doubled too, to 5.0 million people paying $5.99 a month or $69.99 a year for the software side of the product[2][6].
That membership fee is the real pitch to investors. Oura's overall gross margin — what's left after the direct cost of making and delivering the product — is 55%. But the membership piece alone runs at roughly 89%[6]. That's the kind of margin software companies post, not hardware makers. It means investors are being asked to value Oura less like a gadget seller and more like a subscription business that happens to ship a ring first.
Reuters and Bloomberg report Oura is seeking to raise up to $3 billion at a valuation above $16 billion[4][5]. That would be a 45% jump from the $11 billion value set in its $875 million Series E round just a year earlier, in September 2025[5]. Goldman Sachs is leading the offering, with Morgan Stanley, J.P. Morgan and Allen & Company also on board[4][5]. The Motley Fool's take is blunt: Oura, in this framing, "is not just a wearables company anymore"[6] — though that reading treats software-style margins as a settled fact rather than something that still has to survive competition over years, not quarters.
The Pentagon Is the Biggest Customer
Buried in the growth story is a disclosure that's drawing a different kind of attention. Oura says the U.S. Department of Defense is its largest enterprise customer, and in August 2025 the company opened a manufacturing plant in Fort Worth, Texas specifically to serve that business[11]. The relationship dates back to 2019, well before this filing.
Consumer wearables like the Oura Ring sit outside HIPAA, the federal law that governs medical privacy. HIPAA applies to hospitals, doctors and insurers — not to a company selling a ring through its own app[10]. That means whatever protections a user's sleep, heart-rate and temperature data get come from Oura's own policy, not from statute. A policy can change; a law is harder to.
Slate has called the Pentagon relationship "dystopian," and the Mozilla Foundation's privacy review pushes the same question: what happens to that data as the company answers to public shareholders and a large, steady government contract[7][10]. Oura's response is that consumer data is never shared with the Department of Defense unless a service member specifically enrolls in a program and consents[9]. Some coverage has placed Palantir's separate software contract with the Pentagon next to Oura's business relationship in a way that implies a shared data pipeline — but neither company has described one[7].
There's a structural logic on both sides here, not a hidden motive on either. A public company under growth pressure has every reason to lean into its steadiest, largest customer, and federal contracts don't churn the way consumer subscriptions do[11]. Privacy advocates, in turn, have a reasonable structural worry: once biometric data exists at scale outside HIPAA, it becomes a target for future legal demands or policy shifts, regardless of what today's policy says[10].
The Lead That a Courtroom Built
Oura's other edge in the U.S. market isn't just product quality. On September 9, 2025, the U.S. International Trade Commission ruled in Oura's favor in a patent fight against India's Ultrahuman and China's RingConn. Exclusion and cease-and-desist orders took effect October 21, 2025, blocking the rivals' rings from being imported into the U.S.[14]. RingConn settled and took a licensing deal with royalties. Ultrahuman was shut out.
An exclusion order works at the border — it stops products from entering the country, rather than awarding Oura damages for the harm already done[14]. The ITC proceeding also found that Ultrahuman had falsified evidence, including doctoring images to suggest it had a Texas manufacturing facility it didn't have[14]. That finding still shadows the company's attempt to re-enter the U.S. market.
Ultrahuman hasn't stood still. It's redesigned its ring to clear U.S. customs and plans to compete on the point that it charges no monthly subscription at all[13]. Outside the U.S., it's still winning: Ultrahuman held a 30.4% share of India's smart-ring category last year[15]. On September 3, 2026 — the same day Oura filed its S-1 — Ultrahuman announced a $70 million funding round backed by Qualcomm[16]. Indian coverage of the ITC ruling has tended to frame it as a trade barrier keeping a homegrown company out of the world's largest market; U.S. coverage has tended to frame the same ruling as a moat Oura earned. Both readings rest on the same set of facts.
What the Filing Actually Settles
Patents expire, and rivals can design around them before they do. Apple and Samsung, neither bound by the ITC order, could enter the smart-ring category at any point they choose. So Oura's dominance in the U.S. right now rests partly on a legal ruling with a shelf life, not solely on product superiority — a point Ultrahuman and its backers are explicit about[13][14].
Skeptics of the valuation also point to Peloton, which went public in October 2019 on a similar hardware-plus-subscription pitch and later saw its stock fall sharply. If Oura's deal prices near its reported target, it would be the largest consumer-wearables listing since then[5]. That comparison doesn't settle whether Oura's economics are different enough to avoid the same fate — it just explains why some investors are cautious.
None of that changes what's actually happened here. Oura is selling a real product to a real and growing number of people, at real margins, with real net income of $60.8 million over nine months[2]. It's also true that the U.S. government is its biggest enterprise customer, that biometric data outside HIPAA is protected by policy rather than law, and that its two biggest foreign rivals are excluded or licensed by court order rather than out-competed[10][11][14]. Whether Oura is worth more than $16 billion is a bet the market hasn't placed yet. Everything else in the filing is a fact that both sides simply weigh differently — and the underwriters still haven't set a price range or an offering date[4][5].
Summary
Oura, the Finland-founded maker of the Oura Ring, filed a Form S-1 with the U.S. Securities and Exchange Commission on September 3, 2026[1]. An S-1 is the registration document a company must file before it can sell shares to the public. Oura says it will list on the Nasdaq under the ticker OURA[2]. Goldman Sachs is leading the offering, alongside Morgan Stanley, J.P. Morgan and Allen & Company[4][5].
The filing shows fast growth. Revenue was $1.21 billion for the nine months ended June 30, 2026. That is up 74% from $697.6 million in the same nine months a year earlier[2][3]. Paid members doubled to 5.0 million from 2.5 million[2]. The company sold 3.1 million rings in that stretch, up from 1.8 million[2]. Reuters and Bloomberg report the company is seeking to raise as much as $3 billion at a valuation above $16 billion[4][5]. That would be a large step up from the $11 billion value set in its $875 million Series E round in September 2025[5].
The same filing carries two very different bottom lines. Oura earned net income of $60.8 million over the nine months, against $1.6 million a year earlier[2]. But the loss attributable to common stockholders was $924.3 million[2]. The gap comes from a $985.0 million "deemed dividend" — an accounting charge tied to how Oura restructured its preferred shares before the IPO, not cash going out the door[2]. Which of those two numbers a headline uses changes the story a reader takes away.
The genuine dispute is not about the growth numbers, which nobody contests. It is about what the company is worth and what it owes its customers. Supporters point to the subscription business, which the filing shows runs at roughly 89% gross margin — software-like economics on a hardware product[6]. Critics point to two disclosures: the U.S. Department of Defense is Oura's largest enterprise customer[11], and the company's lead over rivals rests partly on a U.S. trade ruling that blocked imports of competing rings from India's Ultrahuman and China's RingConn[14]. Oura says consumer data is never shared with the DoD unless a service member enrolls in a program and consents[9].
The Event
On September 3, 2026, Oura Inc. publicly filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission, seeking to list its shares on the Nasdaq under the ticker symbol OURA[1][2]. The filing disclosed revenue of $1.21 billion for the nine months ended June 30, 2026, 5.0 million paid members as of that date, and 3.1 million rings sold during the period[2]. Goldman Sachs, Morgan Stanley, J.P. Morgan and Allen & Company are named among the underwriters[4][5]. Reuters and Bloomberg report the company is targeting a raise of up to $3 billion at a valuation above $16 billion; no price range or offering date has been set in the filing[4][5].
Undisputed Facts
- Oura Inc. filed a public Form S-1 with the SEC on September 3, 2026, and stated it intends to list on the Nasdaq under the ticker OURA[1][2].
- Revenue was $1.21 billion for the nine months ended June 30, 2026, up 74% from $697.6 million in the same period a year earlier[2][3].
- Fiscal 2025 revenue was $907.9 million, up 123% from $406.8 million in fiscal 2024[2].
- Oura reported net income of $60.8 million for the nine months, and a net loss attributable to common stockholders of $924.3 million after a $985.0 million deemed dividend to preferred holders[2].
- Paid members rose to 5.0 million as of June 30, 2026, from 2.5 million a year earlier; the Oura Membership costs $5.99 a month or $69.99 a year[2][6].
- Overall gross margin was 55%, up from 51%; membership revenue carried a roughly 89% gross margin[6].
- Oura has publicly stated that the U.S. Department of Defense is its largest enterprise customer, and in August 2025 announced U.S. manufacturing operations in Fort Worth, Texas to serve that business[11].
- On September 9, 2025, the U.S. International Trade Commission ruled in Oura's favor against Ultrahuman and RingConn, with exclusion and cease-and-desist orders effective October 21, 2025[14].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Hardware companies must become subscription companies to earn a software multiple
- Investors pay far more for each dollar of recurring subscription revenue than for each dollar of one-time device sales, because subscriptions repeat and carry higher margins. Oura's membership revenue runs at about 89% gross margin against 55% overall[6]. That gap is the entire argument for a valuation above $16 billion on roughly $1.21 billion of nine-month revenue[2][5]. Every part of Oura's public story points at the recurring line.
- The moat is legal, and legal moats have expiry dates
- Oura's U.S. lead rests partly on an ITC exclusion order that blocks rival rings at the border[14]. Patents run out and can be designed around. Ultrahuman has already redesigned its ring for U.S. re-entry[13]. Apple and Samsung face no such barrier if they choose to enter.
- Enterprise revenue is the steadiest revenue, and the government is the steadiest buyer
- Consumer subscriptions churn; federal contracts do not, and they scale in blocks. The DoD is already Oura's largest enterprise customer, and the company built a Fort Worth plant to serve it[11]. That is a sound business reason to deepen the relationship — and the same reason privacy advocates treat it as a one-way ratchet.
- Pre-IPO holders sell before the public buys
- PitchBook reports Oura bought back more than $1 billion from early investors before filing[17]. The $985.0 million deemed dividend in the S-1 is the accounting trace of that pre-IPO restructuring[2]. Insiders got liquidity at a private price; public investors will buy at whatever the offering prices at.
Material realityOura sells a physical ring made of titanium and sensors, and a monthly software service. It shipped 3.1 million rings in nine months and collected $1.21 billion, and it now has 5.0 million people paying $5.99 a month or $69.99 a year[2][6]. The business is genuinely profitable on an operating basis — $60.8 million in net income over the nine months[2]. Those facts do not change with the framing. Neither do these: rings from India's Ultrahuman and China's RingConn are barred from or licensed into the U.S. market by an ITC order, not by any consumer preference[14]; Ultrahuman still leads India with a 30.4% share and just raised $70 million with Qualcomm behind it[15][16]; consumer biometric data sits outside HIPAA, so Oura's privacy commitments are policy, not law[10]; and the U.S. Department of Defense is the company's largest enterprise customer with a dedicated Texas plant behind it[11]. Whether Oura is worth more than $16 billion is a prediction. Everything above is a fact.
Narrative as a weaponThree groups are shaping how this filing reads. Oura and its underwriters want you to see a software company with 89%-margin subscriptions and a defensible patent estate, and to read the $924.3 million loss line as a bookkeeping artifact rather than a business result — which, on the evidence in the filing, it largely is. Consumer-tech and privacy writers want you to read the same filing as a disclosure document about the Pentagon, and to treat a company's promise not to share your sleep data as weaker than a law would be. Ultrahuman and its backers want you to see a contest decided at a trade tribunal rather than in the market, and to see the subscription fee as a cost Oura imposes rather than a service it provides. Notice too that the same S-1 produced headlines saying '$1.21 billion,' '$1.4 billion' and '$2.5 billion' — those are different periods and different measures, and outlets rarely say which. Read the period label before the number.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asOura's pitch is that it is not a gadget company but a health-subscription company that happens to ship hardware. The ring is the sensor; the recurring $5.99-a-month membership is the business[6]. That matters because subscription revenue runs at about 89% gross margin — meaning that of every dollar of membership fees, roughly 89 cents is left after the direct cost of delivering the service[6]. Hardware margins are far thinner. Oura argues the doubling of paid members to 5.0 million shows people keep paying after the novelty wears off[2]. Second, it argues its position is earned, not granted: it spent years building a patent portfolio and defended it successfully at the ITC, which found rivals infringed its claims[14]. Third, it frames the defense work as legitimate performance and readiness research it has done since 2019, with consumer data walled off[9][11].
WhyMaximize the offering price and get long-term investors on the book. A valuation above $16 billion would be roughly 45% above the $11 billion set in the September 2025 Series E[5]. Underwriters earn fees on the size of the raise and want a stock that trades well after listing.
Impact on themA completed IPO at the reported target would raise up to $3 billion in fresh capital and create a public currency for acquisitions and employee pay[4][5]. PitchBook reports Oura also bought back more than $1 billion from early investors ahead of the filing, which let existing holders cash out before public shareholders arrived[17].
Frames it asThe argument is about consent and drift, not about whether Oura is currently breaking a promise. Health wearables sit outside HIPAA, the federal medical-privacy law, because that law covers doctors, hospitals and insurers — not consumer gadget makers[10]. So the only thing limiting what happens to sleep, heart-rate and temperature data is the company's own policy, which a company can change. Critics say a listed company faces steady pressure to grow enterprise revenue, and the largest enterprise buyer is already the Pentagon[7][11]. Mozilla's review argues the burden should be on the company to make its data practices legible, not on the user to parse them[10]. The strongest version of this case is structural: once biometric data exists at scale, it becomes a target for legal demands, breaches and future policy changes.
WhyEstablish that consumer biometric data deserves legal protection comparable to medical records, and to use a high-profile IPO — when a company must disclose its risks in writing — as the moment to force the question.
Impact on themCoverage in Slate, Tom's Guide and NewsNation drove enough user concern that Oura published a public rebuttal[7][8][9]. Oura says consumer data is never shared with the DoD unless a service member enrolls in a specific program and consents[9]. Reporting has also linked the concern to Palantir's separate software work for the DoD; neither company has described a data pathway between Oura's consumer app and Palantir[7].
Frames it asRivals argue that Oura's U.S. lead is partly a legal outcome, not only a product outcome. The ITC's exclusion order bars infringing rings from being imported into the United States — a border remedy, not a damages award, so it removes a competitor from the market rather than making the patent-holder whole[14]. Ultrahuman's answer is to compete on terms Oura does not offer: no monthly subscription, and a redesigned ring built to clear U.S. customs[13]. It also points to markets Oura does not lead. Ultrahuman held a 30.4% share of India's smart-ring category last year[15]. Its stated plan is to show roughly eight quarters of profitability before it lists, rather than going public on growth alone[15].
WhyRegain access to the U.S. market, the single largest one, and reframe the category around hardware people own outright instead of a device that stops being fully useful without a monthly fee.
Impact on themUltrahuman lost U.S. imports as of October 21, 2025 — a market reported to be close to half its revenue[14]. RingConn settled and took a multi-year license with royalties[14]. On September 3, 2026, the same day Oura filed, Ultrahuman announced a $70 million round backed by Qualcomm[16]. The ITC also found Ultrahuman had falsified evidence of a Texas manufacturing facility, a finding the company's critics cite and that shadows its U.S. re-entry[14].
Frames it asThe buy-side question is simple and unsentimental: is this a subscription company or a hardware company? Bulls note that revenue more than doubled in fiscal 2025 and grew 74% in the latest nine months, and that Oura is reporting real net income rather than the losses typical of a consumer-hardware IPO[2]. Skeptics have a specific counter-example: Peloton listed in October 2019 on a similar hardware-plus-subscription story and later fell sharply. They also note that Apple and Samsung can enter the ring category at any time, and that the deemed-dividend line — a $985.0 million charge tied to the pre-IPO share restructuring — is a reminder that reported earnings depend heavily on which line you read[2].
WhyPrice the risk correctly. A large listing at above $16 billion sets a benchmark for other consumer and health-tech companies waiting to go public.
Impact on themIf the deal prices near the reported target, it would be the largest consumer-wearables listing since Peloton's in October 2019[5]. Post-listing trading will set the comparison other private wearables companies are valued against.
Like this article?
The Bias Ledger average rating 4.1
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Reuters | U.S./U.K. wire, center | 2 | "Smart ring maker Oura reveals revenue surge in US IPO filing" — leads with the filing, the ticker, the 74% revenue jump and the underwriter list. | "Surge" is a characterization the wire does not attribute to anyone, but the figure behind it is stated plainly. The deemed dividend and the loss attributable to common stockholders get little room, and the DoD relationship is not in the lead. |
| Fierce Healthcare | U.S. healthcare-industry trade press | 2 | "Smart ring maker Oura files to go public, pitching investors on AI-driven preventive health" — treats the health claims as the company's pitch rather than as fact. | The verb "pitching" is the most careful framing in the set: it attributes the preventive-health claim to Oura instead of adopting it. The trade-press audience is providers and payers, so regulatory and clinical-evidence questions get more room than the valuation does. |
| Bloomberg | U.S. center, financial-markets audience | 3 | "Oura Files for US IPO as Revenue Jumps, Losses Widen in Latest Filing" — pairs the growth with the loss line in the same headline. | The most balanced headline of the set, because it carries both numbers. But "losses widen" without the word "accounting" can read as an operating problem, when the $924.3 million figure comes mainly from the $985.0 million deemed dividend, not from the business burning cash[2]. |
| TechCrunch | U.S. tech trade press, venture-capital-adjacent | 4 | "Qualcomm backs Ultrahuman in $70M round on bet to turn smart rings into computers" — published the same day as Oura's filing, casting the category as a live two-horse race. | Timing is the framing. Running the challenger's funding news against the incumbent's IPO filing implies competitive parity that the U.S. market-share and import-ban facts do not yet support[14][15]. |
| Inc42 | Indian startup-ecosystem trade press | 5 | "Patent Infringement: Oura Wins Initial Victory Against Ultrahuman" — frames the ITC case as a setback for an Indian company facing a Finnish incumbent in a U.S. forum. | Uses "Finland's Oura" as the identifier, keeping the national contest in the frame. Coverage of the ruling emphasizes the U.S. import ban's effect on an Indian firm and gives less prominence to the ITC's specific finding that Ultrahuman falsified manufacturing-facility evidence[14]. |
| The Motley Fool | U.S. retail-investor advocacy; subscription stock-newsletter business model | 6 | "Oura's Revenue Just Jumped 74% — and Its IPO Filing Shows It's Not Just a Wearables Company Anymore" — argues the subscription line, at ~89% gross margin, is the real asset. | Frames a bullish thesis as a discovery in the filing. The publisher sells stock research to retail investors, so upside framing on a hot IPO is native to the format. Competition, churn and the Peloton comparison are not weighted against it. |
| Slate | U.S. left, tech-skeptical commentary | 7 | "Your favorite health wearable has an unexpected—and dystopian—partner" — centers the Pentagon relationship. | "Dystopian" is the writer's own word, not a quoted source. The piece surfaces a real and material disclosure — the DoD is Oura's largest enterprise customer[11] — but places Palantir's separate DoD software work alongside it in a way that implies a connection to consumer data that neither company describes. |